PiTT HOPKINS
RESEARCH FOUNDATION

Don't just hope for MIRACLES, FIGHT for THEM!

PITT HOPKINS NEWSLETTER - September 2025

Pitt Hopkins Awareness Day

Today, on Pitt Hopkins Awareness Day, we celebrate the strength of our children and the dedication of their families. We want to share that there is plans for a celebration of a cure for Pitt Hopkins Syndrome. Our goal is to make this impact is greater, and hope grows stronger.

Please consider joining us in a virtual gathering on Pitt Hopkins Awareness Day, or any other day through the end of September, **or be inspired** on your own to do something for your child, family member, friend, or anyone who needed a cause to fight for.

Let's force our community by attending unique fundraisers, raising funds, and raising hope.

HELP US LIGHT UP THE MAP FOR PITT HOPKINS!

We have been working on:

1. $100,000 in donations by the end of the month, to be matched by an amazing donor!!! We are at $58.00 right now!

2. Donations from all 50 states & as many countries as possible!!! The map below shows where donations are from.

Help us fill in the map & reach our goals, and show Pitt Hopkins & all around the world!

DONATE NOW

Research & Clinical Pipeline 2025

We are looking to enter 2026 with our most ambitious pipeline and advancing multiple therapeutic approaches toward the clinic.

MICROBIOTA TRANSFER THERAPY: We have already had, one patient in a pediatric cohort of the Microbiota Transfer Therapy (MTT) study, achieve a complete resolution of their gastrointestinal manifestations of Pitt Hopkins, which will now continue a pre-set confirmation.

GENE THERAPY: Our gene therapy research was so promising that we were chosen as the lead organization for a collaborative Gene Therapy Consortium for Pitt Hopkins Syndrome, in conjunction with Mahol Therapeutics in late 2024/early 2025.

GENETIC TREATMENTS: We believe the most promising treatment will come through genetic therapy approaches, and we are exploring several options, including ASO, RNA, and CRISPR-based approaches (including Prime Editing). In the approach, we are looking at using various gene therapies to restore the function of the TCF4 gene in the brain. Although we are still in the early stages of these approaches, we want to increase the expression of the good copy of TCF4.

CLINICAL TRIALS: We are actively preparing for a potential Phase 1/2 trial in Rugi can be recruited to begin in 2026 or 2027. We are also working on a natural history study which should begin and significantly ease in the 2H of Pitt Hopkins family. One such component will launch in

CLINICAL TRIALS: We are excited the foundation in 2025, we had a great deal of momentum, and we plan to keep that with a steady. Thanks to the hard work of our team, we have brought two drugs to the clinical stage, and we are on track to bring a third one into the clinic by the end of the year, with multiple more in the pipeline. We are currently in the process of a second SCT trial to see the potential benefit of this approach, and we are also working with Mahol Therapeutics and Ionis Therapeutics to early 2025.

Microbiota Transfer Therapy Microbiota is much more to be done. We need more energy, and review stories of our children and families. We are excited about the MIC-1/GDF15 and ASO MTT trial of Microbiota, Anti-Inflammatory Microbiome Study, Dr. please share, support, and share at

To learn more about our current research, visit

Gene Therapy on the Horizon

Mahol Therapeutics and Pitt Hopkins Research Foundation

A HUGE MILESTONE FOR OUR COMMUNITY!

We are excited to announce that our Gene Therapy clinical trial in partnership with Mahol Therapeutics is on CinicalTrials.gov.

Phase 1/2 study, NCT 06 2 0886, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection in Children and Young Adults with Pitt Hopkins Syndrome

Gene therapy offers exciting possibilities the study will take place, and we are pleased to the near future as it is finalized and approved. We are also excited to share that we will be having a virtual community meeting with Mahol, see details below.

SAVE THE DATE!

Mahol Therapeutics, Pitt Hopkins Foundation and Mahol Therapeutics invite you to a special **Community Meeting** where we will share details about our upcoming **gene therapy clinical trial** for Pitt Hopkins Syndrome.

This is your opportunity to:
- Learn about the trial and what it means for our community
- Hear from the team leading the study
- Connect with other parents and families

Dates & Times (Two Sessions)

Session 1: Tuesday, November 18, 2025 3:00 – 4:00pm EST

Session 2: Wednesday, November 19, 2025 10:00-11:00 AM EST

Attend the session that fits your schedule — content will be similar for both.

This will be a Virtual Event – Link to RSVP is coming soon so be sure and look at social media.

For questions email: information@pittfoundation.org or info@mahol.com

CTL Mahol Therapeutics, and the Pitt Hopkins Research Foundation Announce Collaboration for Clinical Development in Pitt Hopkins Syndrome

CTL Mahol Therapeutics and the **Pitt Hopkins Research Foundation** have joined forces to advance the first gene therapy clinical trial for Pitt Hopkins syndrome. The collaboration centers on Mahol's therapeutic candidate MT-1966, which delivers a working copy of the TCF4 gene via AAV9. This can reach the brain and other tissues.

To put a human face on why this matters, we invite you to watch:

In Memory of Rugi Lagunes with **PHRF President Jessica Fletcher**, sharing a family's everyday life and why this research matters.

These stories remind us why such scientific milestones are a story of love, hope, and community.



Microbiota Transfer Trial Nears Completion

Source: Pitt Hopkins, Dr. Jim Adams

From Dr. Adams: One final study of Microbiota Transplant Therapy for PTHS is going well. 8 participants have completed the study, and 8 are expected to finish by May 2026. Dr Adams and staff appreciate the families who participated in this study and have helped us conduct the study. Here are some quotes from participants who finished the study:

Testimony 1:

Overall, it is such a blessing to have our child in a state where he is feeling great more often.

Testimony 2:

Our son has suffered from severe constipation and reflux ever since he was a baby. We are so happy that our son no longer suffers from constipation and reflux. Most importantly, we've seen a dramatic improvement in his general demeanor. He is happy and comfortable. He especially seems happier and more comfortable at bedtime. We feel that his sleep has improved, and he is generally happier and calmer in his behavior. This realization was life-changing for our son.

Testimony 3:

We are seeing improvements in GI symptoms like reflux and constipation. We also noticed an improvement in behavior, especially on the face and because his face looks happier. We are thinking BG could be a more calm demeanor and is having less discomfort and inattentiveness. Overall my child is happier and calmer.

Testimony 4:

After receiving the MTT for the last two and half years and training, better sleep, less fatigue and anxiety and more focused and happy. Our child's GI issues improved significantly, constipation and gas were now only 10-15 times a day and he had not had a seizure in over 6 months.

The research team at ASU has since launched a company, Co-Bran Ions, with the goal of bringing this therapy widely available. The team is currently in discussions with a seed FDA approved for Pitt Hopkins Syndrome, marking a major step forward for our community.

RVL-001 Clinical Trial for Pitt Hopkins Moving Forward

Big news—again! For the second time in just two weeks, we are thrilled to share that another Pitt Hopkins clinical trial is now live!

This new study, led by our partners at **Ground Biosciences**, will test RVL-001, a gene therapy designed to restore the function of the TCF4 gene in Pitt Hopkins Syndrome (PTHS). Developed by Ionis, dezamizumab inhibits that activity by inactivating gene activity—a promising approach for restoring TCF4 function.

The trial will enroll up to **twelve Canadian participants** and **sixteen** PTHS 247 special physicians. It will be a randomized, double-blind, placebo-controlled study with a dose-escalation design, ensuring safety and effectiveness are carefully monitored. For more details, it is available at ClinicalTrials.gov as NCT06 2 0886.

An Expansion Evaluation of the Safety and Efficacy of Dezamizumab in Pitt Hopkins Syndrome

New Brazilian Pitt Hopkins Association Formed

We are thrilled to celebrate the **official creation of the Associação Brasileira de Síndrome de Pitt-Hopkins (Brazilian Pitt Hopkins Association)**! While Brazil has been a powerhouse in Pitt Hopkins research since 2012, they have now established a formal organization with a board of directors, bylaws, and a clear mission to support families across the entire country.

There are only **100 identified individuals with Pitt Hopkins Syndrome in Brazil**, and most have already made a global impact—helping to spark the development of one of the leading gene therapy approaches for Pitt Hopkins and contributing to the first natural history study in the world.

The association's objectives include funding scientific and therapeutic research, supporting families, advocating for social assistance rights, raising awareness through educational events, partnering with other associations, and building a strong network of families, professionals, and researchers.

PHRF is excited to partnership with this passionate group to strengthen advocacy and accelerate research worldwide. Learn more at www.sindromedepittpittsburgh.com

Mark Your Calendars: Our 2026 Family Conference will be Virtual!

The **Pitt Hopkins Family Conference will be held virtually in 2026**! Bringing our entire global community together online is a powerful way to ensure every family can attend and share stories that matter. Distance and travel shouldn't be barriers, and this format makes it possible for more families than ever to connect, learn, and feel seen. Our conversations, shared stories, and connections will be stronger when we can be together with one another.

Invite expert speakers and scientific updates to share research updates and patient-centered learning activities. The 2026 conference will be packed with valuable information, hope, and connection—and we want you to be a part of it. Learn, ask questions, and connect with others.

And don't worry—we'll be back **in-person in 2027** and we can't wait to see many of you face to face again!

Whether you're joining from a living room or a hospital room, this conference is for you. Mark your calendars, grab your friends, and prepare to be inspired, informed, and forever linked together.

Pitt Hopkins Census

Please joined

- **> 200 Registrations**
- **> 50 Pitt Hopkins Individuals**
- **> 10 Countries**
- **> 10 adults 40 & the youngest registered individual**
- **> 10 years old & the oldest registered individual**

Share details about the information gathered, including a break down of countries, type of diagnosis and age, can be found on our website www.pittfoundation.org/census.

Parents and/or Legal Guardians, We are asking you to please take a couple of minutes and fill out this quick, easy, and very important survey to help us get a more accurate census of diagnosed Pitt Hopkins individuals worldwide.

- **Not to collect** for research, we have stated the survey in multiple languages:

- **English**: https://docs.google.com/forms/d/e/1FAIpQLSfqqq